Clay Siegall: The past, Present, and Future of Breakthrough Therapy

This article is written as a reminder that the fight against is far from over. There have been many great advancements over the past decade, but this deadly disease is still a major concern in society today. Society has been fighting for well over a century, but this is the “21st Century” and cancer has been given it’s walking papers (in-a-sense). Some of the best new treatments in this industry are known as antibody based therapies. These therapies consists of the main weapon of choice known as antibody drug conjugates. (ADCs) are far more advanced than previous medication and treatments to fight this disease thanks to their specific actions. (ADCs) attack cancerous cells and while delivering a fatal blow without ever harming any other cells in the body. This concept is genius as it decreases the chances of the patient having any nasty side effects.

The head man in charge is Dr. Clay Siegall. Even though he isn’t a household, he is probably one of the most known and respected individuals in cancer research. Dr. Siegall is very accomplished in his own rights, but he’s the perfect team player. By implementing strong principles into his foundation is what makes this company stand out. Cancer waits on no one and there is no time to waste. The progressive movements by the good doctor has led Seattle Genetics to the forefront of the industry thanks to it’s innovative line of cancer fighting drugs. The drug ADCETRIS is known as the company’s flagship model as it has increased the survival rates of many when being compared to previous cancer medications. It’s become so successful to where Dr. Siegall has entered it into multiple strategic licensing deals with GlaxoSmithKline, Genentech, and Pfizer. As of today, ADCETRIS has racked up more than $226 Million in the U.S. and Canada alone.

Cancer Research is at a peak thanks to Dr. Clay Siegall and Seattle Genetics stands tall among a crowd of other innovative companies.

Evaluating The Emergence of Seattle Genetics as a Biotechnology Giant

Washington-based biotechnology firm Seattle Genetics, has created a niche for itself as a major player in the biotechnology industry. Since its formation, the firm’s commitment to advancing state-of-the-art cancer therapies, has been steadfast. Seattle Genetics focuses on the developing and commercializing therapies that are antibody-based. This is mainly done through in-depth research, which is conducted by a team of experts led by the firm’s CEO, Dr. Clay Siegall. This high level of commitment has made Seattle Genetics a force to reckon with in the industry.

 

The firm’s breakthrough came after it successfully advanced Adcetris, a cancer therapy that has been commercially availed in more than 60 countries. The firm has banked on the success of this product to come up with many more, all of which have been of great benefit to cancer patients globally. Seattle Genetics boasts a first-class research facility, and a team of proficient scientists, who have been the backbone of its success. It recently started a clinical program, which will test the effectiveness of Adcetris in the treatment of lymphomas.

 

Seattle Genetics has been forming partnerships to enable it market its products to a wider market. It recently partnered with Takeda in a deal that will see it realize the commercial potential that Adcetris has in the United States, Canada and beyond. The company has been driven forward by the desire to alleviate pain and suffering amongst cancer patients. A culture of teamwork, innovation and scientific excellence is encouraged among staff members. It is therefore, not surprising that Seattle Genetics has become a giant in the field of biotechnology.

 

Dr. Siegall in Brief

 

The Maryland and George Washington University alumnus cofounded Seattle Genetics in 1998. Currently, he chairs its board besides being the firm’s president. His experience in the field of biotechnological research has enabled him to offer shrewd leadership to the firm. Dr. Siegall has special interest in the field of Zoology, having pursued the subject up to doctoral level. Prior to co-founding Seattle Genetics, Clay worked at the Bristol-Myers Squibb Pharmaceutical Research Institute. Before that, he had made a name for himself by being one of the most competent researchers at the National Institute of Health.

Sources:

http://www.mirnatherapeutics.com/pdfs/releases/2013%200130%20Mirna%20Siegall%20BOD.pdf